title: Haploidentical transplants using ex vivo T-cell depletion.
abstract: Allogeneic hematopoietic stem cell transplantation (HSCT) is the best post-remission therapy for patients with acute leukemia (AL) at high risk of relapse. Advantages of having a family member as donor include: no undue delay in obtaining the graft; choice of best donor with regards to natural killer (NK) alloreactivity and cytomegalovirus (CMV) status from a panel of candidate family members; easy access to post-transplant cellular therapies like donor lymphocyte infusions and opportunity for a second graft from the original donor, or another family member in case of graft failure. This review will explore how the biological obstacles to HLA-haploidentical (haplo)-HSCT were overcome and how transplant modalities have evolved over time to potentiate the graft-versus-leukemia (GvL) effect in the absence of graft-versus-host disease (GvHD).
authors: Professor Emeritus, Department of Clinical and Experimental Medicine, University of Perugia, Perugia, Italy. Electronic address: mfmartelli39@gmail.com.
authors: Massimo F
authors: MF
authors: Martelli
authors: Hematology and Bone Marrow Transplantation Unit, Department of Clinical and Experimental Medicine, University of Parma, Parma, Italy.
authors: Franco
authors: F
authors: Aversa
mesh_terms: D000818:Animals; D006086:Graft vs Host Disease; D020544:Graft vs Leukemia Effect; D006239:Haplotypes; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007938:Leukemia / Q000628:therapy; D013601:T-Lymphocytes / Q000276:immunology*
keywords: GvL effect; T-cell–depleted haplo-transplant; T-cell–replete haplo-transplant; Tregs adoptive immunotherapy